IL6 and melanoma: Several studies, with the majority of them in ipilimumab-treated melanoma patients, have reported various predictive biomarkers for irAEs, such as level of circulating IL-6, autoantibodies, blood-cell counts, T-cell repertoire, and gut microbiome [132].